Dr. Daniel Von Renteln, MD
Claim this profileCentre Hospitalier Universitaire de Montréal
Studies Colorectal Cancer
Studies Colonic Polyps
12 reported clinical trials
17 drugs studied
Affiliated Hospitals
Clinical Trials Daniel Von Renteln, MD is currently running
Standard Colonoscopy
for Colon Adenomas
During colonoscopy, the endoscopist will document colonoscopy indication; BBPS score; withdrawal time; adenoma and polyp detection rate at index and follow-up colonoscopy; completeness of polypectomy; polyp location, size, surface, morphology (Paris classification), histopathology; complications.
Recruiting1 award N/A
h-APC Margin Ablation
for Colon Polyps
Endoscopic Mucosal Resection (EMR) is the current standard for effective endoscopic resection of such colon adenomas. If resection is possible in one piece (so-called "en bloc" resection) then recurrence rates are low. However, most non-pedunculated polyps \>2 cm are removed in pieces ("piece-meal" resection) which leads to disease recurrence rates between 12-30%. In the March 2019 issue of Gastroenterology Bourke et al. presented that post-EMR ablation of the resection margins using soft coagulation with the tip of a resection snare reduces adenoma recurrence to 5% compared to 21% recurrence found in the control group. Hybrid Argon Plasma Coagulation (h-APC) combines an ablation technique (APC) with the option for submucosal saline injection using a high-pressure water jet. The technique allows to lift of dysplastic epithelium thus creating a safety cushion under the mucosa is lifted with a saline injection and then to ablate larger areas more thoroughly and with a higher energy setting, with a low risk for side effects or complications.
Recruiting1 award N/A3 criteria
More about Daniel Von Renteln, MD
Clinical Trial Related1 year of experience running clinical trials · Led 12 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Daniel Von Renteln, MD has experience with
- Hybrid Argon Plasma Coagulation
- EMR Procedure
- Standard Colonoscopy
- Artificial Intelligence-assisted Classification (CADx)
- Snare Tip Soft Coagulation (STSC)
- Hybrid Argon Plasma Coagulation (h-APC)
Breakdown of trials Daniel Von Renteln, MD has run
Colorectal Cancer
Colonic Polyps
Adenoma
Polyps
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Daniel Von Renteln, MD specialize in?
Daniel Von Renteln, MD focuses on Colorectal Cancer and Colonic Polyps. In particular, much of their work with Colorectal Cancer has involved treating patients, or patients who are undergoing treatment.
Is Daniel Von Renteln, MD currently recruiting for clinical trials?
Yes, Daniel Von Renteln, MD is currently recruiting for 5 clinical trials in Montréal Quebec. If you're interested in participating, you should apply.
Are there any treatments that Daniel Von Renteln, MD has studied deeply?
Yes, Daniel Von Renteln, MD has studied treatments such as Hybrid Argon Plasma Coagulation, EMR procedure, Standard Colonoscopy.
What is the best way to schedule an appointment with Daniel Von Renteln, MD?
Apply for one of the trials that Daniel Von Renteln, MD is conducting.
What is the office address of Daniel Von Renteln, MD?
The office of Daniel Von Renteln, MD is located at: Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec H2X 0A9 Canada. This is the address for their practice at the Centre Hospitalier de l'Université de Montréal (CHUM).
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.